Synergy Pharmaceuticals Inc., of New York, reported $2.3 million in U.S. sales of chronic idiopathic constipation treatment Trulance (plecanatide) during the second quarter, the first full quarter the drug was on the market. The company also recorded approximately $1.5 million in net deferred revenue for product shipped that wasn't prescribed to patients yet. Synergy lost $73.9 million, or 33 cents per share, and ended the second quarter with $82 million in cash and cash equivalents. Shares of Synergy (NASDAQ:SGYP) closed down 13 percent to $3.07 on Thursday.